RedHill Biopharma Amends Share Purchase Agreement
Ticker: RDHL · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Oct 21, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $10,000,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, amendment, equity-deal
Related Tickers: RHBP
TL;DR
RHBP amended its share purchase deal with Alumni Capital LP, watch for potential dilution.
AI Summary
RedHill Biopharma Ltd. announced an amendment to its Any Market Purchase Agreement with Alumni Capital LP, originally entered into on June 20, 2025. This amendment modifies the terms of the agreement under which RedHill has the right to sell shares to Alumni Capital.
Why It Matters
This amendment could impact RedHill's capital structure and share dilution, depending on future share sales to Alumni Capital LP.
Risk Assessment
Risk Level: medium — Amendments to financing agreements can signal financial strain or strategic shifts, potentially impacting stock value.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- Alumni Capital LP (company) — Purchaser in the Any Market Purchase Agreement
- June 20, 2025 (date) — Original date of the Any Market Purchase Agreement
FAQ
What specific terms were amended in the Any Market Purchase Agreement?
The filing states that the agreement was amended, but does not specify the exact terms that were changed.
When was the original Any Market Purchase Agreement entered into?
The original Any Market Purchase Agreement was entered into on June 20, 2025.
Who is the counterparty to RedHill Biopharma in this agreement?
The counterparty is Alumni Capital LP.
What is the purpose of the Any Market Purchase Agreement?
The agreement gives RedHill Biopharma the right, but not the obligation, to sell shares to Alumni Capital LP.
Does this filing provide details on the financial implications of the amendment?
No, the filing announces the amendment but does not detail specific financial implications or dollar amounts related to it.
Filing Stats: 692 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2025-10-21 07:00:08
Key Financial Figures
- $10,000,000 — the Purchaser, from time to time, up to $10,000,000 of American Depositary Shares (" ADSs "
- $500,000 — e purchase price equal to the lesser of $500,000 or thirty percent (30%) of the trading
Filing Documents
- zk2533857.htm (6-K) — 17KB
- exhibit_1-1.htm (EX-99) — 12KB
- 0001178913-25-003530.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the " Registrant ") Date: October 21, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer